Mirati To Present Pooled Clinical Data From Adagrasib's KRYSTAL-1 Study Demonstrating Overall Survival Results At Two-Years Of Follow-Up At 2023 World Conference On Lung Cancer
Portfolio Pulse from Happy Mohamed
Mirati Therapeutics, Inc. (NASDAQ:MRTX) announced a presentation of two-year follow-up from a pooled analysis of the Phase 1/1b Cohort and Phase 2 Cohort A for the KRYSTAL-1 study evaluating adagrasib in patients with non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. The findings will be presented at the 2023 World Conference on Lung Cancer.
August 21, 2023 | 8:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mirati Therapeutics' announcement of the presentation of two-year follow-up data from the KRYSTAL-1 study could potentially boost investor confidence in the company's ongoing research and development efforts.
The announcement of the presentation of two-year follow-up data from the KRYSTAL-1 study indicates progress in Mirati Therapeutics' research and development efforts. This could potentially boost investor confidence in the company's ability to develop effective treatments for non-small cell lung cancer, which could have a positive impact on the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100